Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2023; 83(09): 1102-1116
DOI: 10.1055/a-2121-2495
GebFra Science
Review/Übersicht

Behandlung des frühen Mammakarzinoms

18. Internationaler St.-Gallen-Konsens vor dem Hintergrund der aktuellen deutschen Therapieempfehlungen diskutiert Article in several languages: English | deutsch
Michael Untch   *
1   Klinik für Gynäkologie und Geburtshilfe, interdisziplinäres Brustzentrum, HELIOS Klinikum Berlin Buch, Berlin, Germany
,
Maggie Banys-Paluchowski   *
2   Klinik für Frauenheilkunde und Geburtshilfe, Brustzentrum, Campus Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
,
Sara Y. Brucker   **   #
3   Universitäts-Frauenklinik Tübingen, Tübingen, Germany
,
Wilfried Budach   **
4   Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
,
Carsten Denkert   **   #
5   Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
,
Nina Ditsch   *
6   Klinik für Frauenheilkunde und Geburtshilfe, Brustzentrum, Universitätsklinikum Augsburg, Augsburg, Germany
,
Peter A. Fasching   *
7   Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
,
Renate Haidinger   **
8   Brustkrebs Deutschland e. V., Hohenbrunn bei München, Germany
,
Jörg Heil   **   #
9   Brustzentrum Heidelberg, Klinik St. Elisabeth, Heidelberg, Germany
10   Medizinische Fakultät Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
,
Christian Jackisch   *
11   Klinik für Gynäkologie und Geburtshilfe, Sana-Klinikum Offenbach GmbH, Offenbach, Germany
,
Wolfgang Janni   *
12   Universitätsfrauenklinik Ulm, Ulm, Germany
,
Hans-Christian Kolberg   **
13   Klinik für Gynäkologie und Geburtshilfe, Marienhospital Bottrop gGmbH, Bottrop, Germany
,
David Krug   *
14   Klinik für Strahlentherapie (Radioonkologie), Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
,
Sibylle Loibl   **   #
15   German Breast Group (GBG), Neu-Isenburg, Germany
16   Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany
,
Diana Lüftner   *
17   Immanuel Klinik Märkische Schweiz, Buckow, Germany
18   Immanuel Klinik Rüdersdorf, Medizinische Hochschule Brandenburg, Rüdersdorf bei Berlin, Germany
,
Marion van Mackelenbergh   **
19   Gynäkologie und Geburtshilfe, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
,
Julia C. Radosa   **
20   Klinik für Gynäkologie, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany
,
Toralf Reimer   **
21   Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany
,
Manfred Welslau   **
22   Onkologie Aschaffenburg, Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany
,
Rachel Würstlein   **
23   Brustzentrum, Frauenklinik, LMU Klinikum München, München, Germany
,
Nadia Harbeck   *   #
23   Brustzentrum, Frauenklinik, LMU Klinikum München, München, Germany
,
Jens Huober   *   #
24   Brustzentrum Kantonsspital St. Gallen, St. Gallen, Switzerland
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die diesjährige 18. St.-Gallen-(SG-)Konsensus-Konferenz zur Behandlung des frühen Mammakarzinoms (SGBCC: St. Gallen International Breast Cancer Conference) fokussierte auf praxisorientierte Fragestellungen. Die individuelle Krankheitssituation und Nutzen-Risiko-Abwägung wurden sehr detailliert diskutiert. Wie schon in den vergangenen Jahren hat auch dieses Jahr eine deutsche Arbeitsgruppe führender Brustkrebsexpertinnen und -experten die Ergebnisse der internationalen SGBCC 2023 vor dem Hintergrund der deutschen Therapieempfehlungen – speziell der aktualisierten Therapieempfehlungen der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) – für den Klinikalltag in Deutschland diskutiert. Die deutschen Therapieempfehlungen der AGO basieren auf der aktuellen Evidenz. Der Abgleich mit dem klinischen Vorgehen in Deutschland hat sich bewährt, da sich das SGBCC-Panel aus Expertinnen und Experten unterschiedlicher Länder und Fachdisziplinen zusammensetzt, weshalb länderspezifische Besonderheiten in die SGBCC-Empfehlungen einfließen können.

Schlüsselwörter

St. Gallen Konsensus 2023 - frühes Mammakarzinom - Genetik - Pathologie - Operation - Strahlentherapie - (neo)adjuvante Systemtherapie

* Writing Committee


** Steering Committee


# St. Gallen Panel Expert




Publication History

Received: 25 April 2023

Accepted: 29 June 2023

Article published online:
12 September 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Reference/Literatur

  • 1 AGO Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome (März 2023). Stand: 15.04.2023. Accessed July 30, 2023 at: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
    PubMedGoogle Scholar
  • 2 Tjoung-Won PS, Müller V, Jackisch C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer (EBC): Update 2023. Breast Care 2023; DOI: 10.1159/000531578.
    CrossrefPubMedGoogle Scholar
  • 3 Patridge AH, Niman SM, Ruggeri M. et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med 2023; 388: 1645-1656 DOI: 10.1056/NEJMoa2212856.
    CrossrefPubMedGoogle Scholar
  • 4 Pan H, Gray R, Braybrooke J. et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 2017; 377: 1836-1846 DOI: 10.1056/NEJMoa1701830.
    CrossrefPubMedGoogle Scholar
  • 5 Nelson DR, Brown J, Morikawa A. et al. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS One 2022; 17: e0264637 DOI: 10.1371/journal.pone.0264637.
    CrossrefPubMedGoogle Scholar
  • 6 Yadav S. Population-based Estimates of Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2. San Antonio Breast Cancer Symposium 2022; Abstract No. GS4-04.
    PubMedGoogle Scholar
  • 7 Yadav S, Hu C, Hart SN. et al. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. J Clin Oncol 2020; 38: 1409-1418 DOI: 10.1200/JCO.19.02190.
    CrossrefPubMedGoogle Scholar
  • 8 Tung NM, Robson ME, Ventz S. et al. TBCRC048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 2020; 38: 4274-4282 DOI: 10.1200/JCO.20.02151.
    CrossrefPubMedGoogle Scholar
  • 9 Tutt A, Garber JE, Kaufman B. et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. J Clin Oncol 2021; 39: LBA1 DOI: 10.1200/JCO.2021.39.15_suppl.LBA1.
    CrossrefPubMedGoogle Scholar
  • 10 Tutt ANJ, Garber JE, Kaufman B. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 2021; 384: 2394-2405 DOI: 10.1056/NEJMoa2105215.
    CrossrefPubMedGoogle Scholar
  • 11 de Censi A, Lazzeroni M, Puntoni M. 10-year results of a phase 3 trial of low-dose tamoxifen in non-invasive breast cancer. San Antonio Breast Cancer Symposium 2022; Abstract No. GS4-08.
    PubMedGoogle Scholar
  • 12 Reinisch M, Seiler S, Hauzenberger T. et al. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. JAMA Oncol 2021; 7: 565-572 DOI: 10.1001/jamaoncol.2020.7442.
    CrossrefPubMedGoogle Scholar
  • 13 Offersen B, Alsner J, Nielsen HM. et al. OC-0102 DBCG phase III randomized trial of hypo- vs. standard fractionated RT in 2879 pN+ breast cancer pts. Radiotherapy and Oncology 2022; 170: S76-S77 DOI: 10.1016/s0167-8140(22)02478-1.
    CrossrefPubMedGoogle Scholar
  • 14 Bartelink H, Maingon P, Poortmans P. et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16: 47-56 DOI: 10.1016/s1470-2045(14)71156-8.
    CrossrefPubMedGoogle Scholar
  • 15 Chua BH, Link EK, Kunkler IH. et al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet 2022; 400: 431-440 DOI: 10.1016/s0140-6736(22)01246-6.
    CrossrefPubMedGoogle Scholar
  • 16 Kunkler IH, Williams LJ, Jack WJL. et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16: 266-273 DOI: 10.1016/S1470-2045(14)71221-5.
    CrossrefPubMedGoogle Scholar
  • 17 Kunkler I, Williams LJ, Jack W. et al. GS2-03. Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): Wide local excision and adjuvant hormonal therapy ± whole breast irradiation in women =/> 65 years with early invasive breast cancer: 10 year results. San Antonio Breast Cancer Symposium 2020; Abstract No. GS2-03.
    PubMedGoogle Scholar
  • 18 Moo T-A, Edelweiss M, Hajiyeva S. et al. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?. Ann Surg Oncol 2018; 25: 1488-1494 DOI: 10.1245/s10434-018-6429-2.
    CrossrefPubMedGoogle Scholar
  • 19 Hartmann S, Kühn T, Hauptmann M. et al. Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study. Geburtshilfe Frauenheilkd 2022; 82: 932-940 DOI: 10.1055/a-1889-7883.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Boughey JC, Rosenkranz KM, Ballman KV. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – Results from ACOSOG Z11102 (Alliance). San Antonio Breast Cancer Symposium 2022; Abstract No. GS4-01.
    PubMedGoogle Scholar
  • 21 Gnant M, Fitzal F, Rinnerthaler G. et al. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. N Engl J Med 2021; 385: 395-405 DOI: 10.1056/NEJMoa2104162.
    CrossrefPubMedGoogle Scholar
  • 22 Goss PE, Ingle JN, Pritchard KI. et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375: 209-219 DOI: 10.1056/NEJMoa1604700.
    CrossrefPubMedGoogle Scholar
  • 23 Gray RG, Rea D, Handley K. et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31: 5 DOI: 10.1200/jco.2013.31.18_suppl.5.
    CrossrefPubMedGoogle Scholar
  • 24 Davies C, Pan H, Godwin J. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816 DOI: 10.1016/S0140-6736(12)61963-1.
    CrossrefPubMedGoogle Scholar
  • 25 Johnston SRD, Harbeck N, Hegg R. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38: 3987-3998 DOI: 10.1200/JCO.20.02514.
    CrossrefPubMedGoogle Scholar
  • 26 Harbeck N, Rastogi P, Martin M. et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32: 1571-1581 DOI: 10.1016/j.annonc.2021.09.015.
    CrossrefPubMedGoogle Scholar
  • 27 OʼShaughnessy J, Rastogi P, Harbeck N. Adjuvant abemaciclib combined with endocrine therapy: Updated results from monarchE. ESMO Virtual Plenary Session, October 14, 2021.
    PubMedGoogle Scholar
  • 28 Smith I, Robertson J, Kilburn L. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 2020; 21: 1443-1454 DOI: 10.1016/S1470-2045(20)30458-7.
    CrossrefPubMedGoogle Scholar
  • 29 Nitz UA, Gluz O, Kümmel S. et al. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol 2022; 40: 2557-2567 DOI: 10.1200/JCO.21.02759.
    CrossrefPubMedGoogle Scholar
  • 30 Piccart M, van ʼt Veer LJ, Poncet C. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 2021; 22: 476-488 DOI: 10.1016/S1470-2045(21)00007-3.
    CrossrefPubMedGoogle Scholar
  • 31 Sparano JA, Gray RJ, Ravdin PM. et al. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med 2019; 380: 2395-2405 DOI: 10.1056/NEJMoa1904819.
    CrossrefPubMedGoogle Scholar
  • 32 Kalinsky K, Barlow WE, Gralow JR. et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 2021; 385: 2336-2347 DOI: 10.1056/NEJMoa2108873.
    CrossrefPubMedGoogle Scholar
  • 33 Gluz O, Nitz U, Christgen M. Impact of age, recurrence score and ovarian function suppression on endocrine response to short preoperative endocrine therapy: Analysis of ADAPT and ADAPTcycle trials. Ann Oncol 2022; 33: S808-S869
    CrossrefPubMedGoogle Scholar
  • 34 Sparano J, Gray RJ, Makower D. Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates. San Antonio Breast Cancer Symposium 2022; Abstract No. GS1-05.
    PubMedGoogle Scholar
  • 35 Francis PA, Regan MM, Fleming GF. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446 DOI: 10.1056/NEJMoa1412379.
    CrossrefPubMedGoogle Scholar
  • 36 Schmid P, Cortes J, Dent R. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; 386: 556-567 DOI: 10.1056/NEJMoa2112651.
    CrossrefPubMedGoogle Scholar
  • 37 Schmid P, Cortes J, Pusztai L. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382: 810-821 DOI: 10.1056/NEJMoa1910549.
    CrossrefPubMedGoogle Scholar
  • 38 Loibl S, Schneeweiss A, Huober J. et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022; 33: 1149-1158 DOI: 10.1016/j.annonc.2022.07.1940.
    CrossrefPubMedGoogle Scholar
  • 39 Loibl S, Jackisch C, Rastogi P. et al. GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. Ann Oncol 2019; 30: iii38 DOI: 10.1093/annonc/mdz097.014.
    CrossrefPubMedGoogle Scholar
  • 40 Tolaney SM, Tarantino P, Graham N. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 2023; 24: 273-285 DOI: 10.1016/S1470-2045(23)00051-7.
    CrossrefPubMedGoogle Scholar
  • 41 Tarantino P, Tayob N, Dang CT. Adjuvant Trastuzumab Emtansine versus Paclitaxel plus Trastuzumab for Stage I HER2+ breast cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033). San Antonio Breast Cancer Symposium 2022; Abstract No. PD18-01.
    PubMedGoogle Scholar
  • 42 Loibl S, Jassem J, Sonnenblick A. et al. VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 yearsʼ follow-up. Ann Oncol 2022; 33: 986-987 DOI: 10.1016/j.annonc.2022.06.009.
    CrossrefPubMedGoogle Scholar
  • 43 Loibl S, Huang C-S, Mano MS. et al. Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. NPJ Breast Cancer 2022; 8: 106 DOI: 10.1038/s41523-022-00477-z.
    CrossrefPubMedGoogle Scholar
  • 44 Domchek SM, Postel-Vinay S, Im S-A. et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 2020; 21: 1155-1164 DOI: 10.1016/S1470-2045(20)30324-7.
    CrossrefPubMedGoogle Scholar
  • 45 Konstantinopoulos PA, Waggoner S, Vidal GA. et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol 2019; 5: 1141-1149 DOI: 10.1001/jamaoncol.2019.1048.
    CrossrefPubMedGoogle Scholar
  • 46 Rugo HS, Llombart-Cussac A, Andre F. et al. KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs. pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2020; 38: TPS596 DOI: 10.1200/JCO.2020.38.15_suppl.TPS596.
    CrossrefPubMedGoogle Scholar
  • 47 Gnant M, Pfeiler G, Steger GG. et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 339-351 DOI: 10.1016/S1470-2045(18)30862-3.
    CrossrefPubMedGoogle Scholar
  • 48 Díaz-Roldán J, Eguía-Larrea M, Rubio-Sánchez T. et al. Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease?. Breast Cancer 2022; 29: 9-18 DOI: 10.1007/s12282-021-01293-2.
    CrossrefPubMedGoogle Scholar